Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nanobac Pharmaceuticals has signed a research collaboration agreement with BioChemics to utilize BCI's patented drug delivery technology for the transdermal delivery of Nanobac compounds for the treatment of prostatitis.
Subscribe to our email newsletter
Terms of the deal include upfront payments already made, future payments, R&D support as well as milestones for success for BioChemics (BCI).
John Masiz, president & CEO of BioChemics, said: “Based on the nature of this disease, we believe that the combination of Nanobac’s active pharmaceutical agent combined with BCI’s drug delivery technology may provide a more efficacious treatment therapy for patients suffering from prostatitis.”